CollPlant Biotechnologies (CLGN) Cash from Financing Activities (2018 - 2024)
CollPlant Biotechnologies' (CLGN) quarterly Cash from Financing Activities came in at $9000.0 in Q1 2024, down 98.88% YoY from $803000.0 in Q2 2023, and down 95.83% on a QoQ basis from $216000.0 in Q3 2023.
CollPlant Biotechnologies (CLGN) Cash from Financing Activities (2018 - 2024) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 7 years of Cash from Financing Activities data on file, last reported at $9000.0 in Q1 2024.
- Quarterly Cash from Financing Activities fell 98.88% year-over-year to $9000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $9000.0 (down 99.19% YoY) and the FY2025 annual result came in at $3.1 million, up 34366.67% from the prior year.
- Cash from Financing Activities slipped to $9000.0 in Q1 2024, from $216000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $35.5 million in Q1 2021 to a low of -$54000.0 in Q2 2020.
- A 5-year average of $3.3 million and a median of $308000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 21571.43% in 2020, down 1900.0% in 2020.
- Tracing CLGN's Cash from Financing Activities over 5 years: stood at -$6000.0 in 2020, then jumped by 2466.67% to $142000.0 in 2021, then jumped by 181.69% to $400000.0 in 2022, then sank by 46.0% to $216000.0 in 2023, then tumbled by 95.83% to $9000.0 in 2024.
- The last three Cash from Financing Activities figures came in at $9000.0 (Q1 2024), $216000.0 (Q3 2023), and $89000.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Sep 30, 2023 | 216,000.00 |
| Sep 30, 2023 | 216,000.00 |
| Jun 30, 2023 | 89,000.00 |
| Jun 30, 2023 | 89,000.00 |
| Mar 31, 2023 | 803,000.00 |
| Mar 31, 2023 | 803,000.00 |
| Dec 31, 2022 | 400,000.00 |
| Dec 31, 2022 | 400,000.00 |
| Mar 31, 2022 | 1.47 Mn |
| Mar 31, 2022 | 1.47 Mn |
| Dec 31, 2021 | 142,000.00 |
| Dec 31, 2021 | 142,000.00 |
| Sep 30, 2021 | 1.75 Mn |
| Sep 30, 2021 | 1.75 Mn |
| Jun 30, 2021 | 1.36 Mn |
| Jun 30, 2021 | 1.36 Mn |
| Mar 31, 2021 | 35.51 Mn |
| Mar 31, 2021 | 35.51 Mn |